Charcot-Marie-Tooth Disease Type 2

Charcot-Marie-Tooth disease type 2 (CMT2) is the axonal form of the most common inherited nerve disorder, distinguished from its better-known cousin CMT1 by what goes wrong inside the nerve. In CMT1, the insulating sheath around nerve fibers breaks down. In CMT2, the nerve fibers themselves degenerate, even though their insulation stays largely intact. The result is progressive weakness and wasting in the hands and feet, typically starting in the legs and slowly working its way upward over years or decades. What makes CMT2 especially challenging is that it is not one disease but a sprawling family of conditions caused by mutations in dozens of different genes, each producing subtly different patterns of severity, progression, and sometimes unexpected complications beyond the peripheral nerves.

What Happens Inside the Nerve

The core problem in CMT2 is damage to the axon, the long cable-like projection that carries electrical signals from the nerve cell body to muscles and sensory organs. Healthy axons depend on a constant internal transport system that shuttles mitochondria, proteins, and other cargo along their length. In many CMT2 subtypes, this transport system breaks down. The longest axons, those running from the spinal cord all the way to the toes and fingers, are hit first and hardest because they are the most dependent on that supply chain working flawlessly.

The most common form, CMT2A, is caused by mutations in MFN2, a gene encoding a protein called mitofusin 2 that helps mitochondria fuse together and travel along axons. When MFN2 is mutated, mitochondria cluster abnormally near the cell body instead of distributing evenly along the axon. Researchers have shown that this transport failure happens even though the mitochondria themselves produce energy normally, meaning the problem is not a power shortage but a delivery failure.

¹ Further work using cells from CMT2A patients with different MFN2 mutations confirmed that the energy-producing machinery of the cell is not impaired, reinforcing the view that CMT2A is a trafficking disorder rather than an energy-deficiency disease.²

Other CMT2 subtypes involve different parts of the cellular machinery. CMT2D, for example, is caused by mutations in the gene for an enzyme that attaches the amino acid glycine to its transfer RNA during protein synthesis. That was the first time one of these enzymes had been linked to any human genetic disease.³ In CMT2E and CMT2F, the problem centers on a structural scaffolding protein called neurofilament light chain and a small heat-shock protein, respectively. Both lead to the same downstream catastrophe: the scaffolding inside the axon collapses and clumps together, triggering motor neuron degeneration.⁴

Symptoms and What They Look Like Day to Day

CMT2 usually announces itself with weakness in the feet and lower legs. Foot drop, where you cannot lift the front of your foot properly while walking, is one of the earliest and most recognizable signs. Over time the foot often develops a high arch (pes cavus) and the toes curl into a “hammer” position, making it harder to find comfortable shoes and increasing the risk of calluses and pressure sores. A case report of a teenage patient illustrates the typical picture: distal muscle wasting, clawing of the fingers, pes cavus, hammer toes, and absent reflexes in both legs, with upper-limb reflexes and sensation still preserved.⁵

Hand weakness tends to show up later, making fine tasks like buttoning a shirt or turning a key progressively more difficult. Sensory loss, when it occurs, usually follows the same distal-to-proximal pattern, starting with diminished feeling in the toes and fingertips. Not every CMT2 subtype causes sensory problems to the same degree, though. Some subtypes affect motor neurons far more than sensory ones.

How CMT2 Is Diagnosed

The key diagnostic step that separates CMT2 from CMT1 is a nerve conduction study. In CMT1, the speed of electrical signals traveling along the nerve slows dramatically because the insulating myelin sheath is damaged. In CMT2, signal speed stays close to normal, but the strength of the signal (its amplitude) drops because fewer axons are intact to carry it.⁶ That distinction on the nerve conduction study is usually enough to place a patient in the CMT2 category.

Pinning down the specific genetic subtype is more complicated. With over 100 genes now linked to inherited peripheral neuropathies, the old approach of testing one gene at a time became impractical years ago.⁷ The current standard uses gene panels that screen many CMT-related genes simultaneously. In one large study using these panels, about 30% of patients received a definite genetic diagnosis, with mutations in three genes (GJB1, MFN2, and MPZ) accounting for roughly 40% of confirmed cases. Variants of uncertain significance turned up in another third of patients, leaving their results ambiguous.⁸ That 30% diagnostic yield highlights a persistent frustration: many people with CMT2 still do not have a confirmed genetic cause even after thorough testing.

How Severity and Progression Vary

CMT2 progression is famously unpredictable, even within the same family carrying the same mutation. One of the strongest predictors is age at onset. A study of patients with MFN2 mutations found that those whose symptoms began before age 10 (mean onset around 3.5 years) had more severe disease and faster progression, with about a third of the youngest-onset group eventually becoming wheelchair-dependent. Those with later onset (mean around 20.5 years) tended to have milder impairment and slower decline.⁹

The specific gene matters too. Earlier reports had suggested CMT2E (caused by neurofilament light chain mutations) was always severe and early in onset. Later research challenged that characterization, describing patients with onset anywhere from the first to the fifth decade and severity ranging from mild to moderate.¹⁰ The takeaway is that even within a single genetic subtype, the clinical spectrum can be surprisingly wide.

Clinical overlap with related conditions adds another layer of complexity. A study examining patients initially grouped under CMT2 found that a subset actually had distal hereditary motor neuropathy, a closely related condition that spares sensory nerves entirely. Ages at onset in the combined group ranged from 1 to 70 years, underscoring just how variable the clinical picture can be.¹¹

Exercise and Physical Therapy

For decades, people with CMT were warned against overexerting their muscles out of fear that exercise might accelerate nerve damage. That advice has been largely reversed. A systematic review of rehabilitation approaches found that strength and endurance training improve daily function in people with CMT, and the evidence did not support the old worry about overwork weakness.¹²

The evidence is particularly encouraging for children. A randomized controlled trial in pediatric CMT patients found that six months of targeted progressive resistance exercise slowed the long-term loss of ankle strength without causing muscle damage or other signs of overwork.¹³ Starting exercise early, before significant weakness sets in, seems to offer the best window for slowing progression. The key is supervised, moderate intensity. Nobody is suggesting marathon training, but the old blanket caution against resistance work no longer holds.

Braces, Orthotics, and Foot Surgery

Ankle-foot orthoses are prescribed to most CMT patients with foot drop, and they do help people walk. In one study, participants walked faster and took longer strides with custom braces, and the patients with the weakest ankles gained the most benefit.¹⁴ However, a systematic review and meta-analysis found that while ankle-foot orthoses affected several gait measures, the effect sizes were small to moderate and did not reach statistical significance when pooled across studies.¹⁵ Braces clearly help individual patients in daily life, but the formal evidence base for exactly how much they help on average remains thin.

When foot deformity progresses beyond what braces can manage, surgery becomes an option. The goal is to rebalance the foot: correct the high arch, straighten the toes, and redistribute forces so the foot hits the ground more evenly. One surgical approach combining bone cuts in the first metatarsal with tendon transfers showed that 90% of patients were satisfied with the correction and 70% could walk barefoot afterward. Pain scores dropped roughly in half, and the vast majority reported better foot function and fewer calluses.¹⁶ Recurrence is the main risk; some patients eventually need a more aggressive fusion procedure if the deformity returns. A separate analysis of long-term outcomes confirmed that residual cavus and varus were common after soft-tissue and osteotomy procedures, but functional scores generally remained good.¹⁷

Pain, Fatigue, and Sleep

CMT2 is sometimes described as a painless condition, and that description does patients a disservice. Many people with CMT2 live with chronic pain, fatigue, and disrupted sleep. A case-control study specifically comparing CMT subtypes found that type 2 patients reported more severe pain and fatigue, spent more time awake after falling asleep, and had lower overall sleep efficiency than both healthy controls and CMT1 patients.¹⁸ Nocturnal leg cramps are a common culprit. The combination of neuropathic pain, cramping, and poor sleep can be more disabling than the motor weakness itself for some people, and it often goes underrecognized and undertreated.

When CMT2 Goes Beyond the Peripheral Nerves

Most clinicians think of CMT2 as a disease of the hands and feet, but some cases involve the central nervous system and internal organs. A report of a patient with an MFN2 mutation documented optic nerve atrophy, bladder dysfunction, and weakness of the diaphragm leading to restrictive lung disease, all developing over a 60-year disease course.¹⁹ Optic atrophy in MFN2 mutations is not exceedingly rare; it sometimes shows up as part of a syndrome that overlaps with a separate optic neuropathy caused by the same gene. Breathing problems from diaphragm weakness are rarer but potentially dangerous, especially if they creep in gradually and go unnoticed for years. These atypical features are worth knowing about because they change the monitoring a patient needs.

Emerging Gene and Drug Therapies

There is no approved treatment that slows or reverses the nerve degeneration in any form of CMT2, but research has moved far enough in animal and cell models to start talking about real therapeutic candidates.

For CMT2A, the most advanced approach is gene therapy. Researchers developed a combined strategy that silences the patient’s faulty MFN2 gene while simultaneously delivering a working copy. Tested in motor neurons grown from patient stem cells, this approach corrected the abnormal mitochondrial distribution along axons and fixed defective cellular cleanup processes. When delivered into the spinal fluid of newborn mice carrying a CMT2A mutation using a viral vector, the molecular corrections held up in living tissue.²⁰ A separate group took a simpler approach: instead of silencing the mutant gene, they simply overexpressed normal MFN2 to overwhelm the defective copies. In mice, spinal fluid delivery of this vector restored the contacts between mitochondria and the rest of the cell, preserved the junctions where nerves meet muscles, and reversed locomotor deficits even when injected after symptoms had already appeared.²¹ That last detail, efficacy after symptom onset, is especially promising because most patients are already symptomatic by the time they are diagnosed.

For other CMT2 subtypes, a class of drugs called HDAC6 inhibitors has shown broad potential. These drugs boost the acetylation of a structural protein in axons, which appears to help mitochondria move along the internal transport tracks more efficiently. In cell models of CMT2D (caused by the glycyl-tRNA synthetase mutation), HDAC6 inhibitors restored mitochondrial movement and improved electrical activity across networks of neurons.²² Similar rescue of mitochondrial transport was demonstrated in a neuronal culture model of CMT2F, the subtype caused by heat-shock protein mutations.²³ The appeal of HDAC6 inhibitors is that they might work across multiple CMT2 subtypes by addressing the shared downstream problem of impaired axonal transport, rather than needing to fix each gene individually.

Tracking the Disease With Blood Tests

One of the biggest obstacles to running clinical trials in CMT2 is that the disease progresses so slowly. You might need to follow patients for years before standard clinical exams can detect a meaningful change. Researchers have been investigating whether a protein called neurofilament light chain (NfL), which leaks into the blood when axons are damaged, could serve as a faster readout. Studies have confirmed that blood NfL levels are significantly higher in CMT patients than in healthy controls and that the level correlates, albeit weakly, with how severe the disease appears clinically.²⁴ For CMT2A specifically, NfL appears capable of distinguishing patients from both healthy people and those with other neurological conditions, reinforcing its potential as a biomarker of ongoing axonal damage.²⁵ If validated in larger longitudinal studies, NfL could make clinical trials faster, cheaper, and more sensitive, which in turn would accelerate the path from laboratory discoveries to approved treatments.

Lab Models That Bridge the Gap

A major reason CMT2 research has accelerated in recent years is the ability to grow motor neurons from patient skin cells reprogrammed into stem cells. These patient-derived neurons reproduce key features of the disease in a dish, including the mitochondrial clustering, impaired transport, and abnormal electrical activity seen in living nerves. One study compared neurons from patients with several different CMT2 subtypes and found that progressive mitochondrial and lysosomal trafficking defects were a shared feature across all of them, even though the underlying genetic mutations were different. When the same patient cells were differentiated into sensory neurons instead of motor neurons, only the subtypes known to involve sensory symptoms showed abnormalities, matching what clinicians observe in patients.²⁶ That finding has practical implications: it means researchers can screen drug candidates against these shared defects rather than needing a separate drug program for every genetic subtype, which would be prohibitively expensive for such a rare disease.

Family Planning and Genetic Counseling

Most CMT2 subtypes follow an autosomal dominant inheritance pattern, meaning a parent with the condition has a 50% chance of passing the mutation to each child. Occasionally CMT2 arises from a new spontaneous mutation with no family history. For families where the mutation is known, preimplantation genetic testing during in vitro fertilization is available. A case report documented successful use of this approach for CMT2F: eight embryos were tested, seven were unaffected, four were transferred, and the result was a healthy twin pregnancy.²⁷ Genetic counseling is worth pursuing early, ideally before a couple starts trying to conceive, because knowing the exact mutation opens up reproductive options that are not available once a pregnancy is already underway. Prenatal testing through amniocentesis or chorionic villus sampling is also possible when the family mutation has been identified, though those options raise different ethical considerations since CMT2 is not a life-threatening condition for most people.